Rigel Pharmaceuticals | RIGL - Ebitda


Rigel Pharmaceuticals reported $-4.17M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.8B 1.25B Sep/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -147.68M 40.33M Jun/2026
AstraZeneca USD 7.46B 2.3B Sep/2026
BioMarin Pharmaceutical USD 222.32M 76.27M Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Celldex Therapeutics USD -79.72M 3.86M Jun/2026
Daiichi Sankyo JPY 116.06B 14.46B Jun/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Halozyme Therapeutics USD 336.16M 7.34M Sep/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 74.27M 88.56M Jun/2026
MacroGenics USD -64.54M 34.34M Jun/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Veracyte USD 41.24M 2.72M Sep/2026